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www.cdatm.orgAbstractBackground: Recent observational studies have suggested that the patients with hyperuricemia have a higher risk of having left
atrial thrombus (LATH) or left atrial spontaneous echo contrast (LASEC) by transesophageal echocardiography (TEE), while the
ultimate predictive value of a high uric acid (UA) level on LATH/LASEC remained obscure.
Methods: We searched the PubMed and Cochrane clinical trials databases up to July 2015. Following screening the 369 initially
identified studies, we analyzed six observational studies with 2381 patients.
Results: The meta-analysis of these studies showed that an elevated serum UA level was associated with a higher likelihood of
LATH/LASEC (OR¼ 1.59, 95%CI 1.13e2.23, P¼ 0.008), while significant differences exist among individual trials (P< 0.00001
and I2 ¼ 85%). Sensitivity analysis failed to find any heterogeneity.
Conclusion: An elevated UA level was associated with a higher risk of detecting a left atrial abnormality represented by LATH/
LASEC.
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An atrial thrombus forming in the left atrial
appendage (LAA) in the setting of atrial fibrillation
results in a series of adverse outcomes including
stroke, myocardial infarction and other severe embo-
lism events. Transesophageal echocardiography (TEE)Elsevier B.V. on behalf of KeAi Communications Co., Ltd. This is an
ons.org/licenses/by-nc-nd/4.0/).
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can be helpful when conducting risk stratification of
patients for stroke.1
Hyperuricemia has been shown to be an independent
predictor of cardiovascular events.2 Other studies have
investigated the relationship between high levels of serum
uric acid (UA) and a left atrial thrombus/left atrial spon-
taneous echo contrast (LATH)/(LASEC) as detected by
TEE and there are conflicting results.3e8 We conducted a
comprehensive meta-analysis and systematic review to
investigate the potential relationship between the serum
UA level and left atrial thrombi detected by TEE.
Methods
We conducted this analysis according to the guide-
lines of the Meta-analysis of Observational Studies in
Epidemiology Group (MOOSE).9 Prospective or
retrospective observational studies were enrolled with
the primary objective of analyzing the association be-
tween serum levels of UA and LATH/LASEC. Titles
and abstracts of all articles were evaluated and studies
were rejected if the following inclusion criteria were
not met: 1) human subjects with TEE and correspond-
ing result of LATH/LASEC reported, 2) UA presented
as continuous variable, 3) retrospective/prospective
cohort studies, 4) baseline data available, 5) detail of
LA abnormality detected by TEE mentioned, 6) sample
size of more than 50 patients from individual studies.
Search strategies
We performed a search of the on-line databases of
PubMed and the Cochrane Controlled Trials Register
Databases to July 2015 to identify relevant studies. We
used the following keywords: “uric acid”, “hyperuri-
cemia” and “atrial thrombus”, “spontaneous echo
contrast”, and “left atrium abnormality”. Titles and
abstracts as well as the reference lists of all the iden-
tified reports were independently examined by two
reviewers (E.Z and T.L.) in order to include potentially
relevant studies. The two reviewers agreed on the in-
clusion/exclusion status in 90% of the reviewed
studies. Disagreements were resolved after discussion
with a third reviewer (L.K.). There was no language
restriction for the inclusion of studies. Additionally, we
conducted a manual search using review articles, bib-
liographies of original papers, and abstracts of the
scientific sessions of the American Heart Association,
the European Society of Cardiology, the Heart Rhythm
Society, and the American College of Cardiology from
the past two years.Quality assessment
To limit heterogeneity secondary to differences
between study designs, the quality of each study was
evaluated according to the guidelines developed by the
Evidence-Based Medicine Working Group10 and the
United States Preventive Task Force.11 We applied the
point score system that assessed the following char-
acteristics: (1) clear description of inclusion and
exclusion criteria, (2) study sample representative for
the mentioned population, (3) clear description of
sample selection, (4) full specification of clinical and
demographic variables, (5) complete clinical data such
as renal function and echocardiogram parameters, (6)
no loss of follow-up, (7) cohort study, (8) clear defi-
nition of outcomes and outcome assessment, (9) tem-
porality (assessment of UA level before TEE), and (10)
adjustment of possible confounders in multivariate
analysis. If one of these key points was not mentioned
clearly in a study, we considered it not to have been
performed properly. Therefore, the possibility of un-
derestimation of the reported characteristics may be
present.
Data extraction
Two blind investigators (E.Z. and T.L.) indepen-
dently performed data extraction with a standard data
extraction form to determine eligibility for inclusion.
The following collected information was tabulated: 1)
publication details, first author's last name and the
publication year, 2) characteristics of included studies,
the study population, definition of LA abnormality,
quality score, cohort design, risk estimate, and the
patients' characteristics, 3) baseline data of the studied
population, sample size, age, gender, paroxysmal atrial
fibrillation (PAF) (%), LATH/LASEC (%), uric acid
(mmol/L), creatinine (mmol/L), left atrium diameter,
left ventricle ejection fraction, diabetes mellitus (%),
hypertension (%), body mass index (kg/m2), and left
atrial appendage flow velocity (cm/s).
Statistical analysis
The magnitude of the association between high
serum UA level and the LATH/LASEC detected by
TEE was measured by adjusted OR, or by an OR with
95% confidence intervals (CIs). One study7 only pro-
vided a value of OR by univariate analysis because
there was no association between the serum UA level
and the LATH/LASEC following univariate analysis.
We used the inverse variance method to weight studies
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ined the heterogeneity with the standard c2 test of
heterogeneity. An I2 >50% indicates at least moderate
statistical heterogeneity.12 A pooled effect was calcu-
lated with a random-effects model when the c2-test for
heterogeneity was found to be significant, through
which we could take within-study and between-study
variance into account. Sensitivity analysis was done
by dropping studies and checking the consistency of
the overall effect estimate. Statistical significance for
the treatment effect was defined at P values <0.05.
Publication bias was evaluated using a funnel plot. All
the analyses above were performed using Review
Manager Version 5.3 (Revman; The Cochrane
Collaboration, Oxford, UK).
Results
We identified a total of 369 records following the
primary article search. After screening the titles and
abstracts, 363 studies were discarded because they were
either review articles, laboratory studies, irrelevant to the
current analysis, had insufficient statistics, or were non
cohort studies. After detailed evaluation, sixFig. 1. Flow diagram of stuobservational studies met all inclusion criteria
(Fig. 1).3e8 Overall, therewere 2381 patients involved in
our analysis. The average UA concentration ranged from
279.5 mmol/L5 to 368.8 mmol/L.6 The characteristics of
each included study and baseline data of the patients
from corresponding studies are depicted inTables 1 and 2
respectively. Meta-analysis of the included studies
demonstrated that a higher level of UA was associated
with a higher incidence of LA abnormality (OR ¼ 1.59,
95%CI 1.13e2.23, P ¼ 0.008, Fig. 2), while there are
significant differences between the individual studies
(P < 0.00001 and I2 ¼ 85%). Sensitivity analysis was
performed to seek the origin of heterogeneity. However,
removing any single study did not reduce the heteroge-
neity. The study from Numa et al4 set the broadest defi-
nition of high risk in TEE, which included LATH, dense
LASEC, low LAA flow velocity, and severe aortic
atherosclerosis. However, when we exclude this study,
the results remained positive, which further supported
the close relationship between the high level of UA and
the high incidence of LATH/LASEC (OR¼ 1.67, 95%CI
1.10e2.54, P ¼ 0.02, Fig. 3). Elimination of any study
did not alter the positive association. The funnel plot
(Fig. 4) suggested that there was little publication bias,dy selection process.
Table 1
Characteristics of studies included in meta-analysis.
Investigator Publication
year
Patients (n) Definition of LA abnormality Quality
score
Cohort study
design
Risk
estimate
Patients
characteristics
Liu 2014 525 LATH/SEC 7 N/A aOR AF
Numa 2014 115 TEE thromboembolic risk (TEE risk: low
left atrial appendage flow, spontaneous echo
contrast, thrombi, or aortic atherosclerosis)
8 retrospective aOR CHA2DS2-VASc
score ¼ 0 or 1
Non-valvular AF
Ozturk 2014 207 LATH (presence of a clearly defined
echogenic intracavitary mass with an echo
texture different from that of the underlying
endocardium and not due to the pectinate
muscle)
7 N/A aOR Mitral stenosis and
sinus rhythm
Tang 2014 1359 Well-circumscribed echogenic mass with a
LATH (unique echo texture contrasting with
the adjacent or underlying myocardium)
SEC (atrial blood pool in slow turbulent
blood flow)
8 retrospective aOR Non-valvular AF
Zhao 2015 90 LATH (a fixed or mobile echogenic mass
within the left atrium) SEC (a dense
persistent echogenic swirling pattern that
can be identified in all TEE views regardless
of ultrasound frequency or gain setting)
8 retrospective OR Non-valvular AF
Akpek 2015 85 SEC (a pattern of slowly swirling intracavity
echo densities imaged with gain settings
which were adjusted to distinguish
background noise)
8 retrospective aOR Mitral stenosis
AF: atrial fibrillation; aOR: adjusted odd ratio; N/A: not applicable.
LATH: left atrial thrombus; SEC: spontaneous echo contrast; TEE: transesophageal echocardiography.
Table 2
Baseline clinical characteristics of included studies.
Investigator Publication
year
PAF (%) LATH/SEC (%) Age
(years)
Male (%) UA
(mmol/L)
LAD
(mm)
LVEF (%) CR
(mmol/L)
BMI
(kg/m2)
DM (%) HTN (%) LAAfv
(cm/s)
Liu 2014 83.0 10.9 60.8 64.2 353.9 37.9 N/A N/A N/A N/A N/A N/A
Numa 2014 59.1 28.3 55.4 100 363.0 41.2 58.8 74.3 23.4 N/A N/A 49.1
Ozturk 2014 SR 10.1 41.9 20.8 279.5 44.8 60.8 79.6 N/A 24.6 29.0 35.3
Tang 2014 65.1 4.5 58.2 70.8 368.8 39.0 63.4 83.6 26.2 13.4 51.7 N/A
Zhao 2015 56.7 27.3 60.1 60.0 325.7 40.4 57.7 77.5 N/A 17.8 52.2 N/A
Akpek 2015 39 AF
46 SR
51.8 46.0 34.1 323.2 N/A 62.9 84.1 22.7 28.2 47.1 N/A
PAF: paroxysmal atrial fibrillation; SR: sinus rhythm; LATH: left atrial thrombus; SEC: spontaneous echo contrast; LAD: left atrium diameter;
LVEF: left ventricle ejection fraction; BMI: body mass index; DM: diabetes mellitus; HTN: hypertension; LAAfv: left atrial appendage flow
velocity; N/A: not applicable.
UA: uric acid 1 mg/dl¼ 59.5 mmol/L; CR: creatinine 1mg/dl¼ 88.41 mmol/L; CHA2DS2eVASc: Congestive heart failure, hypertension, Age >75
years, diabetes mellitus, stroke, vascular disease, Age 65e74 years, sex category.
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interpret.
Discussion
Our results showed that higher levels of UA could
predict LATH/LASEC that were detected by TEE.
However, when our investigation was restricted to
patients with atrial fibrillation, we found that high
serum UA level did not predict LATH/LASEC.As a final enzymatic product of purine metabolism,
UA depends on the activity of xanthine oxidase,13 which
participates in the formation of free radical superoxide
anions. A study by Dudley et al showed that the xanthine
oxidase activity in LAA of the AF group was 4.4 times
greater than in the control group14 resulting in local
cellular damage and thrombus formation. The develop-
ment of LATH/LASEC in AF patients may depend on
the type and duration of AF. However, this association
was not defined in the enrolled studies.
Fig. 2. Forest plot of association between high uric acid levels and left atrial thrombus or spontaneous echo contrast detected by transesophageal
echocardiography.
Fig. 3. Forest plot of association between high uric acid levels and left atrial thrombus or spontaneous echo contrast detected by transesophageal
echocardiography excluding the study from Numa.7
Fig. 4. Funnel plot of the meta-analysis.
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close relationship between the presence of AF and
elevated serum UA levels in hypertensive patients.
Inflammation and oxidative stress have been clearly
associated with both progression of AF16,17 and left
atrial abnormality.13,18 However, it is unclear if there is a
direct causal relationship between elevated serum UA
levels andAF.We aimed to determine if abnormal serum
UA concentrations participate in the development ofLATH/LASEC detected by TEE. To the best of our
knowledge, there was no clear evidence supporting the
association between higher serum UA levels and the
detection of LA abnormalities among patients with AF
despite the slight difference found in the total population
when the patients with mitral stenosis and sinus rhythm
were taken into consideration in the present study.
LATH/LASEC is an important risk factor for stroke
in patients with non-valvular AF. A strong association
between higher plasma UA levels on admission and
poor coronary blood flowwas also found in ST-elevation
myocardial infarction patients receiving primary PCI.
Hypercoagulability and thrombus formation may be
reflective of abnormal UA concentrations.19 Zapolski
et al20 also indicated that elevated serum UA could
result in a prothrombotic state. Other epidemiological
studies demonstrated a link between hyperuricemia and
an increased risk of ischemic stroke and mortality.21,22
On the other hand, Chamorro et al23 reported that UA
may provide an additional therapeutic effect in the basis
of thrombolysis among patients with acute stroke. In
addition, some researchers presumed UA elevation had
a compensatory protective mechanism with antioxidant
action.24 The conflicting data encouraged us to weigh
32 E.-Y. Zhang et al. / Chronic Diseases and Translational Medicine 2 (2016) 27e33the merits and demerits of higher UA in AF patients
more carefully.
LATH is a common source of thromboembolism and
can be seen frequently in patients with AF25 and valve
disease (especially mitral stenosis).5,8 However, the
precise mechanism of thrombus formation in LA in the
setting of high serum levels of UA is unclear. The
vascular damage induced by hyperuricemia may be
important as indicated by the excessive oxidant gener-
ation and inflammatory response in vascular endothe-
lium.26,27 UA could promote tissue inflammation and
deterioration of endothelial function, which may be
responsible for AF and accompanying LA thrombus
formation.28 Additionally, hyperuricemia could induce
proliferation of vascular smooth Muscle cell and reduce
the production of vascular nitric oxide leading to
development of turbulent flow and thrombus forma-
tion.29 Moreover, blood flow velocity in LAA may be
another precursor of LATH. It was found to have an
inverse correlation with serum UA levels among 130
patients with AF.30
The mechanism of LATH formation in patients with
mitral stenosis involves inflammation, intra-atrial blood
stasis, and abnormal platelet size and activation.31,32
Exposure to high UA levels leads to a hypercoagulable
condition and further accelerates the LATH formation.5
Conclusion
Our comprehensive meta-analysis shows that
increased serum UA levels could be considered an
independent predictor for LATH or LASEC detected
by TEE. This finding leads to the question of whether
pharmacologic reduction of uric acid can reduce the
risk of stroke. Large prospective studies will be needed
to address this issue.
Limitations
There were several limitations in this meta-analysis.
First, the number of enrolled studies was relatively small
and limited to an Asian population, despite the large
sample size. Second, medications that may have influ-
enced the serum levels of UAwere not reported except
for two studies,6,7 and Tang et al6 excluded patients on
diuretics or allopurinol. Third, the disparity in age and
sex ratio may have affected the UA level as there are
hormonal fluctuations of UA among women at
menarche and menopause.33 Fourth, Numa et al4 only
included patients at low-intermediate clinical risk. Fifth,
Ozturk5 enrolled patients with mitral stenosis and sinus
rhythm, which was significantly different from the otherstudies. Finally, the endpoints defined by individual
studies differ. One study included patients with a low
LAA flow and aortic atherosclerosis as well.4
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